Frequency of Occurrence and Laboratory Features of Rare Coagulopathies. Republican Specialized Scientific and Practical Medical Center Of Hematology of the Ministry of Health of The Republic of Uzbekistan
Keywords:
Rare Blood Clotting Disorders, Hemarthrosis, Coagulopathy, Hemorrhage, Blood CoagulationAbstract
Blood clotting is a process that converts normal liquid blood into a clot that closes the damaged vessel and prevents bleeding. The external and internal pathway of thrombus formation proceeds with the participation of coagulation factors. This process involves the formation of fibrin, a protein that forms the basis of a blood clot. Fibrin as a scaffold gives the thrombus strength. With coagulopathy, due to a lack of coagulation factors, fibrin formation does not occur. Without fibrin, a thrombus is not able to reliably anchor at the site of injury. Uncontrolled bleeding occurs, which can lead to death.
The purpose of this review was to assess the frequency, clinical presentation, genetic basis, possibilities and difficulties in diagnosing these deficiencies. Rare blood clotting disorders (RBCD) include monogenic coagulopathies caused by a deficiency of plasma proteins involved in hemostasis, not related to von Willebrand disease and hemophilia A or B. RBCD include hereditary deficiencies or abnormalities of fibrinogen, prothrombin (factor II), coagulation factors V, VII, X, XI, XII, XIII. All these violations in the overwhelming majority of cases lead to violations of fibrin formation. The reasons for the development of RBCD are, as a rule, recessive inheritance of unique or rare nucleotide changes in genes encoding coagulation factors, or in proteins required for post-translational modifications of these factors. RBCD are most common in ethnic groups in which closely related marriages are accepted, due to the greater likelihood of homozygous carriage of the gene defect.
References
Acharya, S.S., Coughlin, A., Dimichele, D.M. & North American Rare Bleeding Disorder Study, G. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. Journal of Thrombosis and Haemostasis, 2004; 2: 248–256.
Andrew D. Mamford, Writing Group Chair and BCSH Task Force Member Sam Ackroyd, Raza Alikhan, Louise Bowles, Pratima Chowdary, John Grainger, Jason Mainwaring, Mary Mathias and Niamh O’Connell on behalf of the BCSH Committee. Guideline for the license.(http://creativecommons.org/licenses/by/4.0/)
diagnosis and management of the rare coagulation disorders. British Journal of Haematology 2014; 5: 1- 23.
Baumann Kreuziger, L.M., Morton, C.T. & Reding, M.T. Is prophylaxis required for delivery in women with factor VII deficiency? Haemophilia, 2013; 19: 827–832.
Beksac, M.S., Atak, Z. & Ozlu, T. Severe factor X deficiency in a twin pregnancy. Archives of Gynecology and Obstetrics, 2010; 281: 151–152.
Bernardi, F., Dolce, A., Pinotti M., Shapiro, A.D., Santagostino, E., Peyvandi, F., Batorova, A., Lapecorella, M., Schved, J.F., Ingerslev, J., Mariani, G. & International Factor VII Deficiency Study Group. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. Journal of Thrombosis and Haemostasis, 2009; 7: 774–779.
Bowles, L., Baker, K., Khair, K., Mathias, M. & Liesner, R. Prophylaxis with prothrombin complex concentrate in four children with severe congenital factor X deficiency. Haemophilia, 2009; 15: 401–403.
Brown, D.L. & Kouides, P.A. Diagnosis and treatment of inherited factor X deficiency. Haemophilia, 2008; 14: 1176–1182.
Di Minno, M.N., Dolce, A., Mariani, G. & STER Study Group. Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited Ф.VII deficiency. Thrombosis and Haemostasis, 2013; 109: 1051–1059.
Giansily-Blaizot, M., Marty, S., Chen, S.W., Pellequer, J.L. & Schved, J.F. Is the coexistence of thromboembolic events and Factor VII deficiency fortuitous? ThrombosisResearch, 2012; 130: S47–S49.
Girolami, A., Vettore, S., Scarparo, P. & Lombardi, A.M. Persistent validity of a classification of congenital factor X defects based on clotting, chromogenic and immunological assays even in the molecular biology era. Haemophilia, 2011; 17: 17–20.
Girolami, A., Scarparo, P., Bonamigo, E., Treleani, M. & Lombardi, A.M. Homozygous Ф.VII deficiencies with different reactivity towards tissue thromboplastins of different origin. Hematology, 2012; 17: 350–354. license.(http://creativecommons.org/licenses/by/4.0/)
Published
How to Cite
Issue
Section
Copyright (c) 2022 Authors

This work is licensed under a Creative Commons Attribution 4.0 International License.
Article history
- Received: 16 September 2021
- Accepted: 06 December 2021
- Published: 10 January 2022